SCHEMBL7583103

SCHEMBL7583103

CNC(O)(C(C)O)C(C)O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.32
CYP2C19 P33261 1/20 0.32
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8968886 0.83
SCHEMBL21119304 0.76 ALDH1A1 (0.41) ALDH1A1CYP2C19
SCHEMBL27810848 0.73
SCHEMBL28159289 0.71
Water SCHEMBL20657273 0.71
SCHEMBL27471653 0.71 ALDH1A1 (0.30) ALDH1A1CYP2C19
SCHEMBL27416324 0.67
SCHEMBL27825338 0.67 ALDH1A1 (0.33) ALDH1A1CYP2C19
SCHEMBL4598634 0.67 TSHR (0.33)
SCHEMBL12423960 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1245249-A2 Use of a cationic amphipathic compound as a transfection agent, vaccine additive or drug Aventis Pasteur (FR) 2002-10-02 EP disclosed
US-6124270-A IMMUNOLOGY, GENE THERAPY PASTEUR MERIEUX SERUMS ET VACCINS (FR) 2000-09-26 US disclosed
EP-0769942-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1997-05-02 EP disclosed
WO-1996032102-A1 USE OF A CATIONIC AMPHIPATHIC COMPOUND AS A TRANSFECTION AGENT, VACCINE ADDITIVE OR DRUG PASTEUR MERIEUX SERUMS ET VACCINS (FR) 1996-10-17 WO disclosed